KKR-backed Biosynth Carbosynth acquires Vivitide
KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide.
Investment firm KKR has closed its acquisition of UK life sciences company Biosynth Carbosynth, and announced Biosynth's acquisition of vivitide, which provides custom peptides and antibodies for the biotech industry.
Previous vivitide owner Ampersand Capital Partners will become a minority stakeholder in the combined entity. KKR and Ampersand say they plan to accelerate the company’s geographic expansion, broaden its capabilities and expand its product portfolio.
KKR utilized a $4 billion strategic growth fund focused on high-growth health care companies to invest in Biosynth Carbosynth. Company leadership believe the move will position Biosynth Carbosynth as a premium global platform serving high-growth end markets in the life sciences.
Speaking on the acquisition, Biosynth Carbosynth CEO Dr. Urs Spitz said the deal marks an “important milestone” in the company’s journey, adding that Biosynth will “benefit greatly from vivitide’s strong U.S. presence, complementary portfolio of products and services, and entrepreneurial culture.”
Vivitide CEO Dr. Martina Diekmann said she was proud to join forces with Biosynth, noting that the acquisition will allow an acceleration of growth and expanded product offering.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
.png)
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance